@armonadibi's HCG and TRT claims need more context

What did @armonadibi actually say?

The creator is responding to someone who started TRT, noticed testicular shrinkage, and feels terrible. The advice given: testicular shrinkage on TRT is normal, most men don't mind, and the fix is either HCG or gonadorelin. The creator claims "if you take enough HCG it mitigates the shrinkage" and that gonadorelin "does the same thing HCG does." They also warn that quitting TRT cold will likely leave you feeling worse than before you started, with testosterone dropping below pre-treatment levels.

The creator also promotes a clinic they refer people to, which is a financial conflict of interest worth naming outright. That doesn't make everything they said wrong, but it's relevant context.

Does the science back this up?

Mostly, yes, though with meaningful caveats. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Specifically, it shuts down GnRH pulsatility, which stops LH and FSH secretion, which starves the testes of the signal they need to produce testosterone and maintain volume. That's the mechanism behind testicular atrophy on TRT, and it's well-documented.

HCG (human chorionic gonadotropin) mimics LH. It binds to LH receptors in the Leydig cells and stimulates intratesticular testosterone production. Studies have confirmed this works. Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) showed that low-dose HCG co-administration during exogenous testosterone maintained intratesticular testosterone concentrations. Kavoussi et al. (2019, Urology) found HCG preserved testicular volume and function in TRT patients.

Gonadorelin is synthetic GnRH. It stimulates the pituitary to release LH and FSH, rather than acting directly on the testes. The mechanism is upstream of HCG, not identical to it. The creator calling them equivalent is an oversimplification.

What did they get wrong (or right)?

Let's be direct. The claim that gonadorelin "does the same thing HCG does" is inaccurate in a clinically meaningful way. HCG acts directly on testicular LH receptors. Gonadorelin acts on pituitary GnRH receptors to trigger LH release, which then signals the testes. In men on supraphysiologic or even replacement-dose testosterone, pituitary suppression can blunt gonadorelin's effectiveness because the pituitary itself is already suppressed. HCG bypasses that problem entirely. These are not interchangeable drugs.

The HCG shortage claim is accurate. Compound pharmacy access to HCG has been inconsistent, and compounded gonadorelin has emerged partly to fill that gap. However, the creator saying gonadorelin is "pretty much" the same overstates what the evidence actually shows for gonadorelin in this specific application. strong long-term clinical trial data on compounded gonadorelin for testicular maintenance on TRT is limited compared to HCG data.

The warning about coming off TRT causing a temporary drop in testosterone below baseline is legitimate. Post-TRT recovery of the HPG axis takes time, and some men experience a prolonged nadir. That part of the advice is reasonable.

What should you actually know?

If you're on TRT and experiencing testicular atrophy, that is a real and expected physiological consequence, not a myth. The degree varies by individual, dose, and duration. HCG co-administration has the strongest evidence base for preserving testicular volume and intratesticular testosterone production during TRT. Studies like Wenker et al. (2015, Journal of Urology) specifically looked at fertility preservation during TRT and found HCG effective.

Gonadorelin is being used more frequently as compounded HCG availability tightens, but it is not the same drug with the same mechanism, and calling it equivalent without qualification is misleading to patients making treatment decisions. A telehealth provider or urologist should be explaining these distinctions, not glossing over them.

The creator's comment that "most men don't care" about testicular size may be statistically true in some populations, but dismissing a patient's concern as not worth addressing is bad clinical communication. Atrophy is also associated with reduced fertility and potentially affects intratesticular testosterone, which matters for some symptoms. It deserves a real clinical conversation, not a shrug.

Finally, if you feel terrible on TRT, that warrants an investigation, not just a dose adjustment of an adjunct medication. Estradiol levels, hematocrit, thyroid function, and sleep quality all interact with how someone feels on testosterone therapy.